Is pharmaceutical policy evidence-informed? A case of the deregulation process of nicotine replacement therapy products in Finland
Authors:
- Terhi KurkoTKTerhi Kurko
- Antti SilvastASAntti Silvast
- Hannes WahlroosHWHannes Wahlroos
- Kirsi PietiläKPKirsi Pietilä
- Marja AiraksinenMAMarja Airaksinen
- 1 May 2012
- journal article
- Published by Elsevier in Health Policy
- Vol. 105 (2-3) , 246-255
Abstract
No abstract availableKeywords
Funding Information
- Finnish Cultural Foundation
- Association of Finnish Pharmacies
This publication has 19 references indexed in Scilit:
- Community pharmacists' involvement in smoking cessation: familiarity and implementation of the National smoking cessation guideline in FinlandBMC Public Health, 2010
- Nicotine replacement therapy practices in Finland one year after deregulation of the product sales—Has anything changed from the community pharmacy perspective?Health Policy, 2009
- Multimethod research into policy changes in the pharmacy sector—The Nordic caseResearch in Social and Administrative Pharmacy, 2009
- Ten years after the Rx-to-OTC switch of nicotine replacement therapy: What have we learned about the benefits and risks of non-prescription availability?Health Policy, 2008
- The medicine user—Lost in translation?: Analysis of the official political debate prior to the deregulation of the Danish medicine distribution systemSocial Science & Medicine, 2005
- Evidence Of Evidence-Based Health Policy: The Politics Of Systematic Reviews In Coverage DecisionsHealth Affairs, 2005
- Evidence- or opinion-based pharmaceutical policy?Clinical Therapeutics, 2004
- Evidence-based health policy: context and utilisationSocial Science & Medicine, 2004
- Dilemmas In Regulation Of The Market For PharmaceuticalsHealth Affairs, 2003
- Looking for the Evidence in MedicineScience, 1996